FDAapproval54% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Merck.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · NSCLC
- Sub-indication
- Lung Cancer
Related signal: Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC